Simulations Plus, Inc. (NASDAQ:SLP) Shares Acquired by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.

MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in Simulations Plus, Inc. (NASDAQ:SLP) by 4.4% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 9,103 shares of the technology company’s stock after purchasing an additional 380 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd.’s holdings in Simulations Plus were worth $254,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of SLP. Janus Henderson Group PLC grew its holdings in Simulations Plus by 7,753.3% during the fourth quarter. Janus Henderson Group PLC now owns 542,899 shares of the technology company’s stock worth $15,141,000 after acquiring an additional 535,986 shares during the period. Deutsche Bank AG grew its holdings in Simulations Plus by 52.9% during the fourth quarter. Deutsche Bank AG now owns 14,916 shares of the technology company’s stock worth $416,000 after acquiring an additional 5,160 shares during the period. D. E. Shaw & Co. Inc. grew its holdings in Simulations Plus by 100.0% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 53,332 shares of the technology company’s stock worth $1,487,000 after acquiring an additional 26,661 shares during the period. Balyasny Asset Management L.P. acquired a new stake in Simulations Plus during the fourth quarter worth about $424,000. Finally, Ameriprise Financial Inc. grew its holdings in Simulations Plus by 16.7% during the fourth quarter. Ameriprise Financial Inc. now owns 607,902 shares of the technology company’s stock worth $16,954,000 after acquiring an additional 86,868 shares during the period. 78.08% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other Simulations Plus news, Director Walter S. Woltosz sold 20,000 shares of Simulations Plus stock in a transaction on Thursday, May 1st. The stock was sold at an average price of $33.51, for a total value of $670,200.00. Following the sale, the director now owns 3,344,157 shares in the company, valued at $112,062,701.07. The trade was a 0.59% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 19.40% of the company’s stock.

Simulations Plus Price Performance

NASDAQ SLP opened at $31.97 on Friday. The company has a market cap of $642.95 million, a PE ratio of 79.93 and a beta of 1.10. The stock’s 50 day simple moving average is $30.38 and its 200-day simple moving average is $30.42. Simulations Plus, Inc. has a 1-year low of $23.01 and a 1-year high of $50.11.

Simulations Plus (NASDAQ:SLP) last released its earnings results on Thursday, April 3rd. The technology company reported $0.31 earnings per share for the quarter, beating the consensus estimate of $0.25 by $0.06. The business had revenue of $22.43 million for the quarter, compared to the consensus estimate of $21.93 million. Simulations Plus had a return on equity of 6.84% and a net margin of 10.97%. The business’s quarterly revenue was up 22.5% compared to the same quarter last year. During the same quarter last year, the business posted $0.20 earnings per share. On average, equities research analysts anticipate that Simulations Plus, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analyst Weigh In

Several research firms recently commented on SLP. Wall Street Zen raised Simulations Plus from a “sell” rating to a “hold” rating in a report on Monday, April 28th. KeyCorp raised their price objective on Simulations Plus from $32.00 to $40.00 and gave the company an “overweight” rating in a report on Wednesday, April 16th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Simulations Plus presently has a consensus rating of “Moderate Buy” and a consensus target price of $50.00.

About Simulations Plus

Simulations Plus, Inc develops drug discovery and development software for modeling and simulation, and prediction of molecular properties utilizing artificial intelligence and machine learning based technology worldwide. The company operates through two segments, Software and Services. It offers GastroPlus, which simulates the absorption and drug interaction of compounds administered to humans and animals; and DDDPlus and MembranePlus simulation products.